Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Michael Dickinson(The University of Melbourne), Martin Hutchings(University of Copenhagen), Tomasz Wróbel, Guillaume Cartron(Hôpital Saint Eloi), Gloria Iacoboni(Vall d'Hebron Hospital Universitari), Carmelo Carlo‐Stella(Humanitas University), Mark R. Dixon(Roche (United Kingdom)), Emma Clark(Royal Bournemouth Hospital), Franck Morschhauser(Hôpital Claude Huriez), Emmanuel Bachy(Université Claude Bernard Lyon 1), Paolo Corradini(Gruppo di Ricerca Geriatrica), Linda Lundberg(Roche (Switzerland)), Mark Hertzberg(The University of Sydney), James Relf(Roche (United Kingdom)), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Marek Trněný(Charles University), Kathryn Humphrey(Roche (United Kingdom)), Fritz Offner(Ghent University Hospital), David Pérez-Callejo(Roche (Switzerland)), Cyrus Khan(Allegheny Health Network), Shang‐Ju Wu(National Yang Ming Chiao Tung University)
Cited by 718
Related Papers
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907